Abstract
Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients (LTR). BOS is thought to result from chronic immunologic/inflammatory insults leading to peri-bronchiolar leukocyte infiltration, with a subsequent exuberant tissue re-modelling and fibro-obliteration of the luminal space of the allograft airways. Diagnosis is based on functional criteria and severity is graded on the degree of Forced Expiratory Volume in 1 second (FEV1) impairment. Current strategies to improve pulmonary function once BOS is established have demonstrated little or no impact on disease progression and re-transplantation remains the only therapeutic option. Among the alternative treatments which have been attempted in the last few years, long-term azithromycin treatment seems to be the most promising therapeutic device for BOS treatment. Azithromycin is a macrolide antibiotic, endowed with a broad spectrum of anti-inflammatory/immunomodulatory activities. Long-term oral azithromycin therapy can significantly improve FEV1 in about 42% of patients with established BOS. Moreover, reduced neutrophilia, chemokine release and bacterial exacerbations have been demonstrated. These observations suggest that the drug can downregulate pulmonary inflammation, even if the precise underlying mechanisms still need to be determined.
Keywords: Lung transplant, bronchiolitis obliterans syndrome, azithromycin, pulmonary inflammation
Current Medicinal Chemistry
Title: Lung Transplantation: The Role of Azithromycin in the Management of Patients with Bronchiolitis Obliterans Syndrome
Volume: 15 Issue: 7
Author(s): A. M. Fietta and F. Meloni
Affiliation:
Keywords: Lung transplant, bronchiolitis obliterans syndrome, azithromycin, pulmonary inflammation
Abstract: Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients (LTR). BOS is thought to result from chronic immunologic/inflammatory insults leading to peri-bronchiolar leukocyte infiltration, with a subsequent exuberant tissue re-modelling and fibro-obliteration of the luminal space of the allograft airways. Diagnosis is based on functional criteria and severity is graded on the degree of Forced Expiratory Volume in 1 second (FEV1) impairment. Current strategies to improve pulmonary function once BOS is established have demonstrated little or no impact on disease progression and re-transplantation remains the only therapeutic option. Among the alternative treatments which have been attempted in the last few years, long-term azithromycin treatment seems to be the most promising therapeutic device for BOS treatment. Azithromycin is a macrolide antibiotic, endowed with a broad spectrum of anti-inflammatory/immunomodulatory activities. Long-term oral azithromycin therapy can significantly improve FEV1 in about 42% of patients with established BOS. Moreover, reduced neutrophilia, chemokine release and bacterial exacerbations have been demonstrated. These observations suggest that the drug can downregulate pulmonary inflammation, even if the precise underlying mechanisms still need to be determined.
Export Options
About this article
Cite this article as:
Fietta M. A. and Meloni F., Lung Transplantation: The Role of Azithromycin in the Management of Patients with Bronchiolitis Obliterans Syndrome, Current Medicinal Chemistry 2008; 15 (7) . https://dx.doi.org/10.2174/092986708783885228
DOI https://dx.doi.org/10.2174/092986708783885228 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Interactions between Phytochemicals from Traditional Chinese Medicines and Human Cytochrome P450 Enzymes
Current Drug Metabolism Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Subject Index To Volume 1
Recent Patents on Cardiovascular Drug Discovery DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research The Design of Competitive, Small-molecule Inhibitors of Coagulation Factor Xa
Current Topics in Medicinal Chemistry Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design The Role of Heme Oxygenase-1 in T Cell-Mediated Immunity: The All Encompassing Enzyme
Current Pharmaceutical Design MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and Risks
Current Pharmaceutical Design The Bioartificial Kidney in the Treatment of Acute Kidney Injury
Current Drug Targets Memory Improvement with Docosahexaenoic Acid Study (MIDAS)-Brief Review
Current Alzheimer Research Renal-Protective Activity of Dried Gel of <i>Aloe barbadensis</i> (Elwa) on Gentamicin- Induced Nephrotoxicity in Albino Rats
Current Traditional Medicine 20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases
Current Drug Metabolism Chagas Heart Disease Pathogenesis: One Mechanism or Many?
Current Molecular Medicine Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy Effect of Aging On Angiogenesis and Arteriogenesis
Current Cardiology Reviews Glutamate and Mitochondria: Two Prominent Players in the Oxidative Stress-Induced Neurodegeneration
Current Alzheimer Research